Development of novel antagonists of the cell surface adrenomedullin 2 receptor for the treatment of pancreatic cancer (360G-Wellcome-104046_Z_14_C)
Pancreatic cancer is the 10th most common cancer, but in the next 15 years, it will become the second highest cause of cancer-related death. Unlike almost all other cancers, the prognosis has not changed in the last 30 years. After diagnosis, outcomes are very poor, with 1-year and 5-year survival rates of <25% and <5% respectively. The best current therapies offer only a few months of increased life expectancy, and patients’ quality of life is poor despite palliative treatments. There is clearly a pressing need for better treatments for pancreatic cancer. A team from the University of Sheffield led by Professor Tim Skerry, with Peakdale Molecular and Sandexis Medicinal Chemistry have been awarded Seeding Drug Discovery funding to develop selective antagonists of the adrenomedullin-2 receptor. Adrenomedullin is a hormone involved in cancer growth and spread, which also has important roles in the control of blood pressure. Adrenomedullin acts through two different receptors one of which mostly regulates blood pressure. The other has important roles in cancer biology. The team have shown that in model systems, blockade of the receptor reduces tumour growth and spread. They will develop their existing novel lead compounds to block the adrenomedullin-2 receptor and inhibit its important roles in cancer, while keeping its normal functions.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 100000 |
Applicant Surname | Skerry |
Approval Committee | Seeding Drug Discovery Committee |
Award Date | 2017-10-01T00:00:00+00:00 |
Financial Year | 2017/18 |
Grant Programme: Title | Seeding Drug Discovery Award |
Internal ID | 104046/Z/14/C |
Lead Applicant | Prof Timothy Skerry |
Partnership Value | 100000 |
Planned Dates: End Date | 2017-12-19T00:00:00+00:00 |
Planned Dates: Start Date | 2017-11-22T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Yorkshire and the Humber |